First-in-class peptide and monoclonal antibody therapeutics for obesity.
OB-Atlas–driven discovery advancing OB001 and OB002, the first programs in our OB-Series pipeline for obesity and its complications.
SNAPSHOT
OBPharm at a glance
Responses typically within 48 hours
*Preclinical findings; not yet evaluated in humans.
AI PLATFORM
Built around the OB-platform of foundation models.
OB-Atlas models disease biology, OB-Design generates candidates, and OB-Translate drives closed-loop validation—compressing discovery-to-clinic cycles across the OB-Series.
OB-Design (Ab and Peptide)
Structure-guided molecular design for peptides and monoclonal antibodies, combining AlphaFold-class structure prediction, RFdiffusion-style generative models, and iterative in-silico optimization.
OB-Translate
Closed-loop model-to-clinic execution engine linking AI-generated hypotheses, biomarker stratification, and preclinical validation to accelerate IND-enabling decision-making.
OB-Atlas (CKM)
Multimodal cardiometabolic foundation model integrating biomarkers, molecular structure, and phenotypic data to model disease progression and therapeutic response.
PIPELINE
Programs advancing toward the clinic.
Our OB-Series pipeline is led by OB001 and OB002, with additional peptide and monoclonal antibody programs in development.
Lead OB-Series program with differentiated preclinical profile and strong translational rationale.
Follow-on OB-Series program targeting cardiometabolic complications, supported by biomarker-driven discovery.
Additional peptide and monoclonal antibody programs in development across obesity and CKM complications.
PLATFORM
Atlas-guided discovery for obesity and cardiometabolic-renal disease.
We integrate biomarkers, structure, and phenotype to prioritize targets and translate them into differentiated peptide and monoclonal antibody therapeutics.
CAPABILITIES
- Multimodal biomarker & phenotype modeling
- Target prioritization & translational rationale
- Peptide & monoclonal antibody lead optimization
Discovery to Translation
From biomarkers to target selection, lead optimization, and translational rationale.
Preclinical differentiation
Focus on metabolic and inflammatory mechanisms with lean-mass preserving profiles (preclinical).
Partner-ready
Designed for licensing, co-development, and strategic collaborations.
Partner with OBPharm
Reach out for partnering discussions, scientific questions, or to request the latest deck.